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Summary
Background Artemisinin-based combinations are judged the best treatments for multidrug-resistant Plasmodium 
falciparum malaria. Artesunate-meﬂ  oquine is widely recommended in southeast Asia, but its high cost and tolerability 
proﬁ  le remain obstacles to widespread deployment. To assess whether dihydroartemisinin-piperaquine is a suitable 
alternative  to  artesunate-meﬂ  oquine,  we  compared  the  safety,  tolerability,  eﬃ   cacy,  and  eﬀ  ectiveness  of  the  two 
regimens for the treatment of uncomplicated falciparum in western Myanmar (Burma). 
Methods We did an open randomised comparison of 3-day regimens of artesunate-meﬂ  oquine (12/25 mg/kg) 
versus dihydroartemisinin-piperaquine (6·3/50 mg/kg) for the treatment of children aged 1 year or older and in 
adults with uncomplicated falciparum malaria in Rakhine State, western Myanmar. Within each group, patients 
were randomly assigned supervised or non-supervised treatment. The primary endpoint was the PCR-conﬁ  rmed 
parasitological failure rate by day 42. Failure rates at day 42 were estimated by Kaplan-Meier survival analysis. This 
study is registered as an International Standard Randomised Controlled Trial, number ISRCTN27914471. 
Findings Of 652 patients enrolled, 327 were assigned dihydroartemisinin-piperaquine (156 supervised and 171 not 
supervised), and 325 artesunate-meﬂ  oquine (162 and 163, respectively). 16 patients were lost to follow-up, and one 
patient died 22 days after receiving dihydroartemisinin-piperaquine. Recrudescent parasitaemias were conﬁ  rmed in 
only two patients; the day 42 failure rate was 0·6% (95% CI 0·2–2·5) for dihydroartemisinin-piperaquine and 0 (0–1·2) 
for artesunate-meﬂ  oquine. Whole-blood piperaquine concentrations at day 7 were similar for patients with observed 
and non-observed dihydroartemisinin-piperaquine treatment. Gametocytaemia developed more frequently in patients 
who had received dihydroartemisinin-piperaquine than in those on artesunate-meﬂ  oquine: day 7, 18 (10%) of 188 versus 
ﬁ  ve (2%) of 218; relative risk 4·2 (1·6–11·0) p=0·011.
Interpretation  Dihydroartemisinin-piperaquine  is  a  highly  eﬃ   cacious  and  inexpensive  treatment  of  multidrug-
resistant falciparum malaria and is well tolerated by all age groups. The eﬀ  ectiveness of the unsupervised treatment, 
as in the usual context of use, equalled its supervised eﬃ   cacy, indicating good adherence without supervision. 
Dihydroartemisinin-piperaquine is a good alternative to artesunate-meﬂ  oquine.
Introduction
Resistance  to  antimalarial  drugs  has  increased  rapidly 
nearly everywhere in the tropics, and southeast Asia still 
has  the  most  drug-resistant  falciparum  malaria  in  the 
world.
1–3 In Myanmar (Burma), chloroquine has been the 
ﬁ  rst-line treatment for falciparum malaria until recently. 
Studies in 1995 and 1998 by Médecins Sans Frontières 
(Holland), with the support of the Department of Health 
and the Vector Borne Disease Control Department, in the 
western and northern parts of the country showed very 
high rates of resistance to chloroquine and sulfadoxine-
pyrimethamine,  the  recommended  treatments  at  the 
time.  Meﬂ  oquine  monotherapy  (15  mg/kg)  had  failure 
rates of 7% in Rakhine State, in the west of the country,
3 
and 20% in Kachin State, in the north.
4 Thus, there was 
resistance  to  all  available  monotherapies.  Combination 
therapy that includes an artemisinin derivative is now the 
preferred ﬁ  rst-line treatment for malaria. 
In  Myanmar,  a  3-day  treatment  of  meﬂ  oquine  and 
artesunate  was  highly  eﬃ   cacious,  even  when  the 
treatment was not fully supervised.
5 In September, 2002, 
the Myanmar Department of Health changed the national 
protocol  for  ﬁ  rst-line  treatment  of  uncomplicated 
falciparum  malaria  to  a  3-day  artesunate-meﬂ  oquine 
treatment  (artesunate  12  mg/kg  and  meﬂ  oquine 
25 mg/kg). This change was an important step forward 
but  there  are  several  obstacles  to  implementing  the 
policy.  First,  the  high  price  of  artesunate-meﬂ  oquine 
(around US$3 for one adult treatment) means that this 
regimen is not accessible to most people with malaria, 
who are therefore still treated with chloroquine. Second, 
adverse  eﬀ  ects  are  common  after  meﬂ  oquine,  and 
although most side-eﬀ  ects are not serious, they can lead 
to poor adherence with multiple-dose regimens. Third, 
meﬂ  oquine and artesunate are not yet formulated in one 
tablet, so patients can take only the artesunate, thereby 
compromising eﬃ   cacy and encouraging resistance. 
Two  old  drugs,  dihydroartemisinin  and  piperaquine, 
have been formulated in a new combination treatment. 
Several  studies  in  southeast  Asia  indicate  that  this 
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combination is a safe and highly eﬃ   cacious treatment 
for  uncomplicated  multidrug-resistant  falciparum 
malaria  in  adults  and  children.
6–9  Compared  with 
artesunate-meﬂ  oquine,  dihydroartemisinin-piperaquine 
has  several  potential  advantages.  First,  it  is  cheaper 
(around US$1·50 for an adult treatment), which might 
improve  access  to  eﬀ  ective  antimalarial  treatment  for 
poor  populations.  Second,  available  data  suggest  that 
dihydroartemisinin-piperaquine is better tolerated than 
is  artesunate-meﬂ  oquine.
7  Third,  the  combination 
treatment is formulated in one tablet, which makes it 
easier to take, and should increase adherence and thereby 
limit the chance for selection of resistant parasites. Until 
recently, dihydroartemisinin-piperaquine was produced 
in the People’s Republic of China and Vietnam, but the 
available products did not meet internationally accepted 
standards for good manufacturing practices.
In Myanmar, as in most countries, intake of antimalarial 
drugs is generally not supervised. Furthermore, treatment 
is  unlikely  to  be  supervised  in  the  foreseeable  future, 
with the exception of the ﬁ  rst dose, which can be given in 
the health clinic. Highly eﬃ   cacious treatments may not 
be eﬀ  ective if adherence to the prescribed treatment is 
poor. Adherence is related to the adverse-eﬀ  ect proﬁ  le. To 
assess this issue and inform policy we did a four-way 
randomised  trial  to  compare  the  safety,  tolerability, 
eﬃ   cacy,  and  eﬀ  ectiveness  of  dihydroartemisinin-
piperaquine with that of artesunate-meﬂ  oquine for the 
treatment of uncomplicated falciparum malaria in adults 
and children in western Myanmar. 
Methods
Study area and population 
The  study  was  done  in  two  village-tracts,  Dabhine  and 
Mingan, which are about 10 km apart, in the township of 
Sittwe along the coast of the Bay of Bengal, in Rakhine 
State,  western  Myanmar.  In  this  region,  malaria  trans-
mission is seasonal (May–January) with peaks during the 
post-monsoon (November–January) and sometimes in the 
early  monsoon  (May–June)  periods.  The  transmission 
intensity  is  geographically  heterogeneous,  varying  from 
low to high over short distances. Plasmodium falciparum 
causes around 80% of the malaria infections that present 
to the clinics. 
In 1994, Médecins Sans Frontières (Holland) started to 
support a malaria control programme in Rakhine State 
in cooperation with the Vector Borne Disease Control 
Department. The programme focuses on early diagnosis 
and treatment. Since 1996, all patients with falciparum 
malaria  accessing  this  programme  have  been  treated 
with a combination of meﬂ  oquine and artesunate. The 
programme supports 30 ﬁ  xed clinics and three mobile 
malaria clinics, which visit remote areas by boat. In 2003, 
the  programme  provided  a  diagnostic  test  to  300 000 
patients, of whom around 150 000 had falciparum malaria 
conﬁ  rmed  and  received  a  3-day  combination  treat-
ment  with  artesunate  and  meﬂ  oquine  (artesunate 
12 mg/kg+meﬂ  oquine 25 mg/kg). Our prospective study 
was done between November, 2003, and April, 2004. 
If patients had fever (axillary temperature ≥37·5º C) or a 
history of fever within 48 h, a blood smear was prepared. 
Patients with conﬁ  rmed falciparum malaria were invited 
to take part in the study if they had more than 500 but 
fewer than 100 000 asexual parasites per μL, no clear signs 
or symptoms of other diseases, and no signs of severe or 
complicated  malaria.  Children  younger  than  1  year, 
pregnant women, patients with severe malaria,
10 patients 
with  a  history  of  taking  meﬂ  oquine  in  the  previous 
2 months or any other antimalarial drugs in the previous 
48 h, and patients with a history of psychiatric diseases 
were excluded from the study. Patients with mixed infection 
(P  falciparum  with  P  vivax,  P  malariae,  or  both)  were 
included.  Patients  who  met  the  inclusion  criteria  were 
enrolled in the study only after fully informed consent was 
obtained  from  them  or  their  carer.  The  protocol  was 
approved by the Myanmar Department of Health and by 
the Médecins Sans Frontières ethics review board.
Procedures
Patients  were  stratiﬁ  ed  prospectively  into  three  age 
groups (1–4 years, 5–14 years, and older than 14 years) 
and allocated randomly to the four treatment regimens. 
At both study locations three boxes were prepared, one 
for each of the three age groups, by an administrator who 
was otherwise not connected with the study. In each box, 
40  unmarked  and  sealed  opaque  envelopes  were 
deposited. Each envelope contained a card that described 
the treatment assignment, and each treatment allocation 
had an equal number of cards (ten). Each new patient (or 
his or her carer) was asked to take one of the envelopes 
from the box for their age group. Treatment was then 
dispensed in accordance with the treatment allocation in 
the envelope. Whenever a box became empty, another 
40 envelopes were put in that box. 
All  patients  were  examined  clinically.  A  gametocyte 
count was done, blood was taken for measurement of the 
haemoglobin concentration, and a blood spot was taken 
on  ﬁ  lter  paper  for  PCR  examination.  Each  PCR  ﬁ  lter 
paper was dried, put in an individual plastic bag, and 
kept in an airtight box with silica gel.
This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN27914471.
Antimalarial drug regimens
The patients were randomly allocated to four treatment 
groups. The ﬁ  rst group was assigned supervised dihydro-
artemisinin-piperaquine  (Artekin,  Holleykin  Pharma-
ceuticals, Guangzhou, China). The drug was given in a 
dose of 2·1 mg/kg dihydroartemisinin and 16·8 mg/kg 
piperaquine once daily for 3 days. Patients took every dose 
under supervision in the clinic. The number of pills was 
rounded oﬀ   to the nearest half tablet. The usual adult dose 
was three tablets per day. The second group was assigned 
unsupervised  dihydroartemisinin-piperaquine  in  the Articles
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same  doses  as  the  ﬁ  rst  group.  The  ﬁ  rst  dose  was 
supervised, but the treatments on days 1 and 2 were self-
administered at home. Group three was assigned 3-day 
treatment with meﬂ  oquine (Lariam, Hoﬀ  man-La Roche, 
Basel, Switzerland) 25 mg base/kg single dose on day 0, 
and  artesunate  (Guilin  Pharmaceutical  Factory,  Guilin, 
China) 4 mg/kg on days 0, 1, and 2. Every dose was given 
under supervision in the clinic. The number of pills was 
rounded oﬀ   to the nearest quarter of a tablet. The usual 
adult dose was ﬁ  ve tablets of meﬂ  oquine in one dose, and 
four tablets of artesunate per day. The fourth group was 
assigned the same drugs and the same doses as group 
three, but with the ﬁ  rst dose supervised and the treatments 
on day 1 and day 2 self-administered. 
The  diﬀ  erences  in  drug  formulations  meant  that 
masking of treatment at the point of administration was 
not  possible.  For  the  drugs  that  were  to  be  self-
administered in treatment groups 2 and 4 on days 1 and 
2, two stapled small plastic bags were provided, marked 1 
and  2,  with  the  medication  for  the  next  2  days.  The 
importance of taking these drugs, even if symptoms had 
already  subsided,  was  explained  twice.  All  other 
antimalarial drug doses were given under the supervision 
of a treatment observer for 1 h. For children, tablets were 
crushed  and  syrup  was  added.  If  the  patient  vomited 
within 30 min, the full dose was repeated. Patients who 
vomited  between  30  min  and  60  min  after  drug 
administration  were  given  half  the  initial  dose.  If  the 
patient vomited the drugs twice, he or she was withdrawn 
from the study. For patients who vomited after 1 h, no 
repeat treatment was given and the patient remained in 
the study. Patients from treatment groups 1 and 3 were 
asked  to  return  to  the  clinic  on  the  next  2  days  for 
supervised doses. Patients in these groups who missed 
doses in the mornings of days 1 and 2 were traced within 
24 h, and the drugs were given under direct supervision. 
Patients from the unsupervised treatment groups (2 and 
4) were asked to come back if they vomited within 1 h of 
drug administration.
Patients were requested to come back routinely on 
days 1 and 2 (only for the supervised treatment groups 
1 and 3) and on days 7, 14, 21, 28, 35, and 42 after 
starting treatment (for all treatment groups) and at any 
other time when they felt unwell or thought they had 
fever. At each routine visit, a blood ﬁ  lm was taken for 
the  identiﬁ  cation  of  malaria  parasites,  a  gametocyte 
count was done, and a questionnaire was completed 
(for patients 4 years of age or older) to document side-
eﬀ  ects. On day 7, the questionnaire for side-eﬀ  ects was 
detailed retrospectively for each day of the week (days 
3–7 for groups 1 and 3, and days 1–7 for groups 2 and 
4).  Additionally,  one  blood  sample  (100  μL  taken  by 
micropipette) was kept on a ﬁ  lter paper on day 7, which 
was  used  later  for  the  measurement  of  the  blood 
concentration  of  piperaquine.  On  day  28,  a  blood 
sample  was  obtained  for  repeat  haemoglobin 
measurement. 
Repeat  treatment  was  provided  to  patients  who 
deteriorated clinically at any time, and those who returned 
on  days  2–6  with  patent  P  falciparum  parasitaemia  of 
more than 25% of the count on day 0. Patients who had 
persistent parasitaemia on days 2–6 but less than 25% of 
the  initial  parasite  count  and  fever  (but  no  clinical 
deterioration)  were  not  deﬁ  ned  as  having  treatment 
failure. These patients were followed up closely to ensure 
that no further deterioration took place. Repeat treatment 
was also provided to patients with P falciparum parasites 
on day 7 or any subsequent day. 
For patients treated previously with dihydroartemisinin-
piperaquine the repeat treatment was with artesunate-
meﬂ  oquine  if  there  was  no  contraindication,  and  for 
patients who received artesunate-meﬂ  oquine previously 
it  was  dihydroartemisinin-piperaquine.  Mode  of 
administration (supervised or not) was the same as for 
the initial treatment. Patients with treatment failure were 
followed  up  in  the  same  way  as  those  whose  ﬁ  rst 
treatments had failed.
 From all patients whose treatment failed, additional 
blood was obtained on a ﬁ  lter paper for PCR genotyping. 
Patients with a positive blood smear for P vivax, P ovale, 
or  P  malariae  were  not  deﬁ  ned  as  having  treatment 
failure. They were given chloroquine (25 mg base per kg 
during 3 days) and follow-up was continued. 
To  distinguish  recrudescences  from  new  infections, 
parasite genotypes were established on admission and in 
cases of recurrent parasitaemia. Parasite genotyping was 
done with PCR for variable blocks within MSP1, MSP2, 
and  GLURP  as  described  previously.
11  If  a  deﬁ  nitive 
statement could not be made, the outcome was recorded 
as indeterminate. Treatment failure rates were calculated 
for  patients  with  proven  recrudescences  only  and  for 
patients  with  recrudescences  or  indeterminate  PCR 
outcomes. The primary outcome measure was the rate of 
recrudescence conﬁ  rmed with PCR.
Piperaquine whole-blood concentrations were measured 
by  solid-phase  extraction  and  liquid  chromatography.
12 
The blood spots were cut into pieces and extracted with 
perchloric acid, phosphate buﬀ  er pH 2 containing internal 
standard, and acetonitrile for 1 h. The supernatants were 
loaded onto an MPC solid-phase extraction column (3M 
Empore,  Bracknell,  UK);  the  eluates  were  evaporated, 
reconstituted, and injected into a liquid chromatography 
system with a Chromolith performance column (VWR 
International, Darmstadt, Germany) and a mobile phase 
containing  acetonitrile-phosphate  buﬀ  er  pH  2·5 
0·1 mol/L (8:92 by volume) at a ﬂ  ow rate of 3 mL/min. 
The  total  precision  for  all  quality  controls  during  the 
analysis was 11·5% at 0·2 μg/mL, 10·9% at 0·75 μg/mL, 
and 7·4% at 2·5 μg/mL.
Statistical analysis 
This trial was designed as a non-inferiority study. With a 
sample size of 160 patients in the four study groups, a cure 
rate of 95% with either drug regimen could be estimated Articles
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with 5% precision, and a maximum allowable inferiority of 
10%  for  dihydroartemisinin-piperaquine  compared  with 
artesunate-meﬂ  oquine could be detected with 90% power 
and 95% conﬁ  dence, taking into account a withdrawal rate 
of up to 20%. Data were analysed with SPSS for Windows 
version  11.5,  STATA  version  9,  and  EpiInfo  version  6. 
Continuous  data  were  analysed  by  Student’s  t  test  or 
ANOVA,  and  proportions  of  categorical  data  were 
compared by χ
2 test with Yates’ correction or a two-tailed 
Fisher’s exact test. Comparisons between treatment groups 
were  done  in  a  two-way  factor  analysis:  ANOVA  for 
continuous data and multiple logistic regression model for 
categorical data. The eﬀ  ect of the treatment on recurrence 
of  falciparum  malaria  was  summarised  by  the  risk 
diﬀ  erence.  Eﬀ  ects  of  the  treatment  on  other  secondary 
outcomes were summarised by relative risks.
As a measure of transmission potential, we calculated 
the person-gametocyte-weeks, which were deﬁ  ned as the 
number of weeks in which blood slides were positive for 
gametocytes during the ﬁ  rst 2 weeks of follow-up after 
treatment divided by the number of weeks followed up, 
and were expressed per 1000 person-weeks.
13 Failure rates 
were  estimated  by  survival  analysis  with  the  Kaplan-
Meier method. Patients who did not complete follow-up 
or had a new infection were censored at the time they 
were last seen.
CIs around failure rate estimates were calculated by 
Greenwood’s formula. When failure rates were zero, CIs 
were calculated by the exact binomial method with the 
eﬀ  ective sample sizes.
14 Equivalence between treatment 
groups  was  assessed  by  calculating  the  diﬀ  erences 
between  failure  rates  and  the  CIs  around  these 
diﬀ  erences. CIs were based on the eﬀ  ective sample sizes 
as above and calculated with the Score method.
15
Recurrences  that  were  indeterminate  on  the  PCR 
analysis were treated ﬁ  rstly as censored observations and 
secondly as failures (to describe the worst-case scenario). 
Role of the funding source
The sponsors of the study had no role in the study design, 
data  collection,  data  analysis,  data  interpretation,  or 
writing of the report. The corresponding author had full 
access  to  all  the  data  in  the  study  and  had  ﬁ  nal 
responsibility for the decision to submit for publication. 
Results
Between  November,  2003,  and  February,  2004, 
15 228 patients were screened, but 14 576 were not eligible 
(ﬁ  gure 1). 1261 refused consent, mostly because they lived 
far from the clinic and because part of the study period 
was during Ramadan, which made it diﬃ   cult for patients 
to comply with the follow-up requirements.
652  people  met  the  inclusion  criteria  and  were 
recruited  for  the  study.  Of  them,  156  were  assigned 
dihydroartemisinin-piperaquine  (supervised),  171  dihy-
dro  artemisinin-piperaquine  (home),  162  artesunate-
15 228 patients screened
14  576 ineligible
8952 no malaria
1190 parasitaemia 
outside range
1150 <500/µL
40 >100 000/µL
55 gametocytes only
3111 P vivax
7 pregnant
1261 refused consent 
652 patients randomised
156 dihydroartemisinin-
         piperaquine supervised
         38 <5 years  
         93 5–14 years
         25 >14 years
171 dihydroartemisinin-
        piperaquine not
        supervised
        41 <5 years
        98 5–14 years
        32 >14 years
162 artesunate-
         meﬂoquine supervised
         37 <5 years
         96 5–14 years
         29 >14 years
163 artesunate-
         meﬂoquine not
         supervised
         43 <5 years
         93 5–14 years
         27 >14 years
4 lost to follow-up 3 lost to follow-up
1 died
5 lost to follow-up 4 lost to follow-up
152 analysed at day 42 167 analysed at day 42 157 analysed at day 42 159 analysed at day 42
Figure 1: Trial proﬁ  leArticles
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meﬂ  oquine (supervised), and 163 artesunate-meﬂ  oquine 
(home). 399 patients were recruited in Dabhine and 253 
in  Mingan.    Baseline  characteristics  were  comparable 
across groups (table 1), with the exception of gameto-
cytaemia on admission.
One  11-year-old  child  died  during  the  study.  He  had 
received dihydroartemisinin-piperaquine (not super  vised). 
During the follow-up visits on days 7 and 14, he had no 
fever  and  the  blood  smears  were  negative  for  malaria 
parasites. On the evening of  day 20, the child developed 
fever. The next morning he had generalised seizures and 
his parents took him to the local hospital. The hospital 
physician noted decreased consciousness but no signs of 
meningism.  A  blood  smear  for  malaria  parasites  was 
negative. The physician treated for cerebral malaria and 
bacterial  meningitis  with  a  loading  dose  of  quinine, 
intravenous penicillin, and chloramphenicol. Nevertheless, 
the child died the next day. No autopsy was done.
16 other patients (2·5%) did not complete the 42 day 
follow-up period (ﬁ  gure 1). These patients were included 
in the data analysis for the period they participated. 
Early responses to treatment could be measured only in 
the  supervised-treatment  groups,  who  returned  to  the 
clinic on days 1 and 2. Of these patients, the proportions 
whose  parasitaemia  had  cleared  after  1  day  were  53% 
(82 of 155) after dihydroartemisinin-piperaquine and 45% 
(73 of 161) after artesunate-meﬂ  oquine (relative risk 1·17 
[95%  CI  0·93–1·46],  p=0·22).  After  2  days  the  pro-
portions of patients who had cleared parasitaemia were 
97%  (151  of  155)  after  dihydroartemisinin-piperaquine 
and  94%  (150  of  159)  after  artesunate-meﬂ  oquine, 
respectively. Of the remaining nine infections in the latter 
group, eight were P falciparum and one P vivax.
At baseline, 44% of patients in each supervised group 
were  febrile  (table  1).  1  day  after  treatment  these 
proportions had dropped to 3% in both treatment groups 
(four of 155 and four of 161, respectively). All patients had 
clearance of their parasites by day 7.
  Only  seven  patients  had  reappearance  of  parasites 
within  42  days,  one  after  artesunate-meﬂ  oquine 
(supervised) and six after dihydroartemisinin-piperaquine   
(four  supervised,  and  two  unsupervised).  The  relative 
risk for recurrent parasitaemia for dihydroartemisinin-
piperaquine  versus  artesunate-meﬂ  oquine  was  5·96 
(0·72–49·26, p=0·12). Two patients presented with fever, 
whereas the other ﬁ  ve were asymptomatic. Of the seven 
patients  with  recurrent  parasitaemias,  all  were  aged 
between 3 years and 6 years. Parasite genotyping was 
done on paired samples. In three patients a new genotype 
was conﬁ  rmed, indicating a new infection (all 28 days 
after supervised dihydroartemisinin-piperaquine). In two 
patients,  recrudescent  parasitaemias  were  conﬁ  rmed 
(one patient 14 days after dihydroartemisinin-piperaquine 
[home] and one patient 28 days after dihydroartemisinin-
piperaquine  [supervised]). Of the two remaining patients, 
the PCR results were indeterminate (one patient 28 days 
after  dihydroartemisinin-piperaquine    [supervised]  and 
one patient 35 days after artesunate-meﬂ  oquine [super-
vised]).  If  recurrences  of  parasitaemias  that  were 
indeterminate  on  the  PCR  analysis  were  treated  as 
censored ﬁ  ndings, the failure rate was 0·6% (95% CI 
0·2–2·5)  for  dihydroartemisinin-piperaquine  and 
0 (0–1·2) for artesunate-meﬂ  oquine, and the diﬀ  erence 
between  the  two  treatment  groups  was  0·63% 
(–0·66 to 2·28, p=0·16). However, if we assume that the 
PCR-indeterminate recurrences were treatment failures 
(the  worst-case  scenario),  the  failure  rate  was  0·9% 
(0·3–2·9) for dihydroartemisinin-piperaquine and 0·3% 
(0–2·2)  for  artesunate-meﬂ  oquine,  and  the  diﬀ  erence 
between  the  two  treatment  groups  was  0·63% 
(–0·94 to 2·46). The four treatment groups were therefore 
regarded as therapeutically equivalent because all CI for 
diﬀ  erences were well within the 10% limits. 
At  baseline,  87  patients  had  mixed  infections  with 
P vivax (85 children and two adults). On day 7, all P vivax 
infections  had  cleared  but  97  patients  had  presumed 
Dihydroartemisinin-
piperaquine (supervised)
Dihydroartemisinin-
piperaquine (home)
Artesunate-meﬂ  oquine 
(supervised)
Artesunate-
meﬂ  oquine (home)
Number of patients 156 171 162 163
Women  79 (51%) 83 (49%) 72 (44%)  79 (49%)
Age groups (years)
<5  38 (24%) 41 (24%) 37 (23%) 43 (26%)
5–14  93 (60%) 98 (57%) 96 (59%) 93 (57%)
>14  25 (16%) 32 (19%) 29 (18%) 27 (17%)
Axillary temperature ≥37·5ºC 69 (44%) 79 (46%) 72 (44%) 69 (43%)
Haemoglobin g/L (SD) 94 (22) 92 (22) 95 (21) 95 (22)
Anaemic* 92 (59%) 113 (66%) 91 (56%) 95 (59%)
Geometric mean parasite count/μL (range) 8128 (627–91 741) 9593 (585–99 502) 7663 (560–90 480) 8365 (600–96 792)
Mixed infections 21 (14%) 19 (11%) 23 (14%) 24 (15%)
Gametocytaemia on admission 70 (45%) 67 (39%) 58 (36%) 45 (28%)
Data are number (%) unless stated otherwise. *Haemoglobin concentration <100 g/L. 
Table 1: Clinical and laboratory variables at baselineArticles
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relapses of this species during follow-up (three patients 
had  two  vivax  episodes;  table  2).  The  median  time  to 
appearance  of  P  vivax  malaria  was  42  days  for 
dihydroartemisinin-piperaquine (supervised), 39 days for 
dihydroartemisinin-piperaquine (home), and 35 days for 
both artesunate-meﬂ  oquine groups. Patients who received 
artesunate-meﬂ  oquine had more vivax infections during 
follow-up  (57  of  316)  than  patients  who  received 
dihydroartemisinin-piperaquine    (40  of  319),  but  this 
diﬀ  erence  was  not  signiﬁ  cant  (relative  risk  0·70 
[0·48–1·01], p=0·07). Children younger than 5 years were 
more likely to have vivax malaria during follow-up  (61 of 
154, 40%) than older children (36 of 375, 10%) or adults 
(none of 106; p<0·0001). Of the 87 patients who had mixed 
infections  at  baseline,  22  (25%)  had  relapses  of  vivax 
malaria during follow-up, whereas 75 (13%) of 565 patients 
who did not have mixed infections at day 0 had subsequent 
relapses (relative risk 1·86 [95% CI 1·22–2·83], p=0·007).
At  baseline,  240  (37%)  of  652  patients  had  patent 
gametocytaemia  (table  1).  The  proportions  with 
gametocytaemia diﬀ  ered between the treatment groups 
despite  randomisation,  with  higher  proportions  of 
gametocytaemia  in  the  dihydroartemisinin-piperaquine 
groups than in the artesunate-meﬂ  oquine groups (table 1). 
The gametocyte carrier rate was higher in young children 
(85 of 159, 54%) than in older children (131 of 380, 35%) 
or adults (24 of 113, 21%; p<0·0001; table 3). There was a 
strong  association  between  anaemia  and  gametocyte 
carriage. The proportion with patent gametocytaemia at 
baseline  was  highest  in  patients  with  haemoglobin 
concentration less than 80 g/L (35 of 78, 45%); 25% (26 of 
110) of patients with haemoglobin of 80–100 g/L, and 19% 
(24 of 128) of those with haemoglobin more than 100 g/L, 
had gametocytaemia at baseline. In a stepwise multiple 
regression model both haemoglobin concentration and 
age were independently correlated with gametocytaemia 
(haemoglobin p<0·0001, and age p=0·008)
In the weeks after treatment, the gametocyte carriage 
rate decreased gradually and gametocytes were cleared by 
day 21 for both artesunate-meﬂ  oquine groups, day 35 for 
the  dihydroartemisinin-piperaquine  (home)  group,  and 
day 42 for the dihydroartemisinin-piperaquine (supervised) 
group (table 4, ﬁ  gure 2). New gametocytaemia was also 
more  common  in  the  dihydroartemisinin-piperaquine 
groups than in the artesunate-meﬂ  oquine groups on day 7 
(18 of 188 [10%] and ﬁ  ve of 218 [2%], respectively; relative 
risk 4·17 [1·58–11·03]; p=0·011) and on day 14 (three of 168 
and one of 212, respectively; 3·79 [0·40–36·07], p=0·12). 
Gametocyte carriage rates, measured as person-gametocyte-
weeks per 1000 person-weeks, were signiﬁ  cantly higher for 
the dihydroartemisinin-piper  aquine groups than for the 
artesunate-meﬂ  oquine groups (table 4, p=0·003).
P falciparum P vivax
Cumulative conﬁ  rmed recrudescence and reappearances 
of parasitaemia with indeterminate PCR results  
New infections Reappearances
Day 14 Day 28 Day 42 Day 7–42
Dihydroartemisinin-piperaquine  (supervised)
Age 0–14 years 0/130 1/129 (1%)* 1 /129 (1%)* 3 22/129 (17%)
Age >14 years 0/24 0/24  0/23  0 0/23 
Total 0/154 1 /153 (1%)* 1 /152 (1%)* 3 22/152 (15%)
Dihydroartemisinin-piperaquine (home)
Age 0–14 years 1/138 (1%)* 2 /137 (2%)† 2/137 (2%)† 0 18/137 (13%)
Age >14 years 0/31 0/31  0/30  0 0/30 
Total 1/169 (1%)* 2 /168 (1%)† 2/167 (1%)† 0 18/168 (11%)
Artesunate-meﬂ  oquine (supervised)
Age 0–14 years 0/129 0/129  1/129 (1%)‡ 0 25/129 (19%)
Age >14 years 0/29 0/28  0/28  0 0/28 
Total 0/158 0/157  1/157 (1%)‡ 0 25/157 (16%)
Artesunate-meﬂ  oquine (home)
Age 0–14 years 0/135 0/134  0/134  0 32/134 (24%)
Age >14 years 0/25 0/25  0/25  0 0/25 
Total 0/160 0/159  0/159  0 32/159 (20%)
*One conﬁ  rmed recrudescence. †One conﬁ  rmed recrudescence and one indeterminate PCR result. ‡One indeterminate PCR result.
Table 2: Parasitological responses to antimalarial treatment 
<5 years 5–14 years >14 years p 
Gametocytes (+) day 0  85/159 (54%) 131/380 (35%) 24/113 (21%) <0·0001
Gametocytes (+) day 7  54/153 (35%) 101/377 (27%) 21/110 (19%) 0·003
New gametocyte appearances on day 7  3/150 (2%) 17/360 (5%) 3/107 (3%) 0·60
New gametocyte appearances on day 14  1/69 (1%) 3/230 (1%) 0/81 (0%) 0·37
χ² test for linear trend.
Table 3: Relation between gametocytaemia and ageArticles
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The mean haemoglobin concentration at baseline did 
not  diﬀ  er  in  the  four  treatment  groups,  and  25%  of 
patients  had  severe  anaemia  (haemoglobin  <80g/L; 
table 1). On day 28, this proportion had decreased to 
10% (64 of 631).  The mean increases in haemoglobin 
did  not  diﬀ  er  across  the  groups  (p=0·36,  table  5). 
Haemoglobin  concentrations  were  lower  in  young 
children (mean 83 g/L) than in older children (93 g/L) 
and  adults  (112  g/L).  The  mean  haemoglobin 
concentrations increased to 95 g/L, 102 g/L, and 113 g/L, 
respectively, for the three age groups by day 28. The 
increase in haemoglobin concentrations was signiﬁ  cantly 
greater for the younger groups (p<0·0001).
Adverse eﬀ  ects were reported most frequently in the 
ﬁ  rst week and were more commonly reported by patients 
in  the  supervised  treatment  groups  than  the  non-
supervised groups (table 6). All patients were observed 
for 1 h after treatment on day 0. Overall 15 patients (2·3%) 
vomited  within  that  time.  On  day  1,  treatment  was 
monitored  only  for  the  supervised  groups.  In  these 
groups, eight patients vomited within 1 h (four in each 
drug group). On day 2, only two patients vomited, both 
from  the  dihydroartemisinin-piperaquine  group.  The 
patients in the non-supervised groups came back for the 
ﬁ  rst time on day 7. None reported vomiting within 1 h of 
taking  the  medicines  on  days  1  or  2.  Thus,  vomiting 
within  1  h  was  signiﬁ  cantly  more  common  in  the 
supervised  than  in  the  unsupervised  groups  (ten  of 
635 observations vs none of 668, p=0·0007). Vomiting on 
day  0  within  1  h  of  drug  administration  was  more 
common in young children (ten of 159) than in older 
children (four of 386) and adults (one of 113, p=0·001).
Dizziness was the most frequently reported complaint. 
In  the  supervised  groups,  the  proportion  of  patients 
reporting dizziness within 24 h of taking the tablets was 
signiﬁ  cantly  smaller  for  the  dihydroartemisinin-
piperaquine  group  than  for  the  artesunate-meﬂ  oquine   
group (47 of 133, 35% vs 72 of 151, 48%; relative risk 0·74 
[0·56–0·98], p=0·05). There was a similar pattern for the 
dihydroartemisinin-piperaquine (home) and artesunate-
meﬂ  oquine (home) groups (38 of 144, 26% vs 55 of 138, 
40%;  0·66  [0·47–0·93],  p=0·02).  The  next  day  the 
frequencies of dizziness had decreased. Dizziness was 
again reported less in the dihydroartemisinin-piperaquine 
groups than the artesunate-meﬂ  oquine groups but these 
diﬀ  erences  were  not  signiﬁ  cant:  18%  (24  of  134)  after 
supervised dihydroartemisinin-piperaquine and 27% (41 
of  150)  after  supervised  artesunate-meﬂ  oquine  (0·66 
[0·42–1·02],  p=0·08);  and  19%  (28  of  144)  after 
dihydroartemisinin-piperaquine treatment at home and 
28%  (38  of  138)  after  artesunate-meﬂ  oquine  at  home 
(0·71  [0·46–1·08],  p=0·14).  After  day  2  the  proportion 
reporting dizziness was 3% or less for all groups. 
Nausea was also less frequently reported within 24 h of 
taking the tablets in the dihydroartemisinin-piperaquine   
(supervised)  group  than  in  the  artesunate-meﬂ  oquine   
Dihydroartemisinin-
piperaquine 
(supervised)
Dihydroartemisinin-
piperaquine (home)
Artesunate-meﬂ  oquine 
(supervised)
Artesunate-meﬂ  oquine 
(home)
Relative risk (95% CI) for 
dihydroartemisinin-
piperaquine (all) vs 
artesunate-meﬂ  oquine (all)
p
Positive for gametocytes
Day 0  70/156 (45%) 67/171 (39%) 58/162 (36%) 45/163 (28%) 1·32 (1·08–1·62) 0·006
Day 7  58/153 (38%) 60/169 (36%) 33/158 (21%) 25/160 (16%) 2·01 (1·53–2·64) <0·0001
Day 14  43/153 (28%) 41/165 (25%) 14/158 (9%) 3/160 (2%) 4·94 (3·00–8·13)* <0·0001
Day 21 14/149 (9%) 12/167 (7%) 0/154  0/156  ·· <0·0001† 
Day 28 3/152 (2%) 3/166 (2%) 0/156  0/158  ·· 0·03†
New gametocyte appearances
Day 7  7/84 (8%) 11/104 (11%) 3/102 (3%) 2/116 (2%) 4·17 (1·58–11·03)  0·011
Day 14  3/78 (4%) 0/90  1/99 (1%) 0/113  3·79 (0·40–36·07) 0·115
Person-gametocyte-weeks 330 (101/306) 302 (101/334) 149 (47/316) 88 (28/320) 0·003‡
p values are adjusted for supervision (home vs supervised) unless stated otherwise. *Eﬀ  ect of treatment diﬀ  ers for supervised and home groups (p=0·04). Relative risk 13·25 (4·19–41·93) for home groups and 3·17 (1·81–5·56) for 
supervised groups. †Not adjusted for supervision. p value is from χ² test with Yates’ correction. ‡Calculated with the Score test.
Table 4: Gametocyte responses to antimalarial treatment  
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Figure 2: Proportions of patients with patent gametocytaemiaArticles
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(supervised) group  (21 of 134, 16% vs 35 of 151, 23%; 0·68 
[0·41–1·10],  p=0·15).  For  the  patients  who  took  the 
treatment at home the proportions were 13 of 144 (9%) 
for dihydroartemisinin-piperaquine, and 19 of 138 (14%) 
for artesunate-meﬂ  oquine (0·71 [0·46–1·08]). The next 
day the proportion reporting nausea in the supervised 
groups  had  fallen  to  2%  (two  of  132)  after 
dihydroartemisinin-piperaquine and 13% (17 of 133) after 
artesunate-meﬂ  oquine (0·12 [0·03–0·50], p=0·0009) and 
in  the  home  groups  to  7%  (ten  of  134)  after 
dihydroartemisinin-piperaquine and 7% (ten of 138) after 
artesunate-meﬂ  oquine  (1·03  [0·44–2·39],  p=0·87).  On 
day 3, only one patient reported nausea. Adults reported 
signiﬁ  cantly  more  dizziness  (p<0·0001)  and  nausea 
(p=0·0002) than children in the ﬁ  rst week.
Other side-eﬀ  ects such as anorexia, diarrhoea, itchiness, 
abdominal  pain,  and  fatigue  were  less  common,  and 
their occurrence was not linked to the speciﬁ  c treatment 
groups.  In  the  dihydroartemisinin-piperaquine  group, 
three patients reported mild itching; two on day 0 and 
Dihydroartemisinin-
piperaquine (supervised)
Artesunate-meﬂ  oquine 
(supervised)
Relative risk 
(95% CI ) 
p  Dihydroartemisinin-
piperaquine  (home)
Artesunate-meﬂ  oquine 
(home)
Relative risk 
(95% CI ) 
p 
Dizziness 60/134 (45%) 84/150 (56%) 0·8 (0·63–1·01)  0·08 44/144 (31%) 60/138 (44%) 0·7 (0·51–0·96) 0·03
Nausea 24/133 (18%) 43/149 (29%) 0·63 (0·40–0·97) 0·05 15/144 (10%) 22/138 (16%) 0·65 (0·35–1·21)  0·23
Anorexia 8/133 (6%) 14/149 (9%) 0·64 (0·28–1·48) 0·40 2/144 (1%) 5/138 (4%) 0·38 (0·08–1·94) 0·27
Diarrhoea 9/133 (7%) 7/149 (5%) 1·44 (0·55–3·76)  0·62 2/144 (1%) 2/138 (1%) 0·96 (0·14–6·71)  1·0
Itchiness 2/133 (2%) 0/149 (0%) .. 0·22 1/144 (1%) 0/138 (0%) .. 1·0
Abdominal pain 2/133 (2%) 4/149 (3%) 0·56 (0·10–3·01) 0·69 1/144 (1%) 1/138 (1%) .. 1·0
Fatigue 1/133 (1%) 5/149 (3%) 0·22 (0·03–1·89) 0·22 0/144 (0%) 1/138 (1%) .. 0·49
Vomiting day 0
Within 30 min 2/144 (1%) 5/149 (3%) 0·41 (0·08–2·10) 0·45 4/165 (2%) 2/153 (1%) 1·67 (0·31–9·0) 0·69
30–60 min 0/144 (0%) 1/149 (1%) .. 1·0 1/165 (1%) 0/153  .. 1·0
Vomiting day 1
Within 30 min 0/156 1/162 (1%) .. 1·0 0/171 0/163 .. ..
30–60 min 4/156 (3%) 3/162 (2%) 1·38 (0·31–6·09) 0·73 0/171  0/163  .. ..
Vomiting day 2
Within 30 min  1/155 (1%) 0/162 .. 0·49 0/171  0/163  .. ..
30–60 min 1/155 (1%) 0/162 .. 0·49 0/171 0/163  .. ..
χ² test with Yates’ corrected p values.
Table 6: Adverse eﬀ  ects within the ﬁ  rst week after treatment 
Dihydroartemisinin-
piperaquine 
(supervised)
Dihydroartemisinin-
piperaquine (home)
Artesunate-meﬂ  oquine 
(supervised)
Artesunate-
meﬂ  oquine (home)
Relative risk (95% CI) for 
dihydroartemisinin-
piperaquine (all) versus 
artesunate-meﬂ  oquine (all)
p 
All age groups
Mean haemoglobin (g/L)
Day 0  94 92 95 95 .. 0·15
Day 28 104 101 103 102 .. 0·65
Change  9·4 9·1 8·1 8·1 .. 0·36
Proportion of people anaemic*
Day 0 92/156 (59%) 113/171 (66%) 91/162 (56%) 95/162 (59%) 1·13 (0·99–1·28)  0·18
Day 28 56/152 (37%) 75/165 (46%) 59/156 (38%) 68/158 (43%) 1·02 (0·85–1·23) 0·85
Children <5 years
Mean haemoglobin (g/L)
Day 0 84 78 82 87 .. 0·18
Day 28 96 89 95 99 .. 0·06†
Change  12 10 13 12 .. 0·46
Proportion of children anaemic*
Day 0 27/38 (71%) 37/41 (90%) 30/37 (81%) 34/43 (79%) 1·04 (0·90–1·21)  0·85
Day 28 19/37 (51%) 29/39 (74%) 17/33 (52%) 22/43 (51%) 1·23 (0·93–1·63)  0·12
Continuous data were analysed by two-way ANOVA and proportions of categorical data were compared with multiple logistic regression model. p values adjusted for eﬀ  ect of supervision (supervised vs home). *Haemoglobin 
<100g/L. †Eﬀ  ect of the treatment diﬀ  ered for supervised group and  home treated groups (p=0·03).
Table 5: Haemoglobin values after treatment Articles
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one  on  day  7.  The  itching  was  mild,  did  not  need 
treatment,  and  had  disappeared  at  the  next  visit.  No 
patient needed hospital admission for side-eﬀ  ects.
The median blood piperaquine concentration on day 7 
was  63  ng/mL  (IQR  49–86;  n=299);  28  samples  were 
unavailable  because  of  instrument  failure.  The 
concentrations were similar for the supervised (median 
62 ng/mL [50–82]; mean 72 ng/mL) and home treatment 
groups  (median  66  ng/mL  [47–90  ng/mL];  mean 
74 ng/mL; p=0·66 for comparison of medians; ﬁ  gure 3). 
Six patients had piperaquine concentrations lower than 
the limit of quantiﬁ  cation (25 ng/mL), of whom two had 
treatment  failure  (one  recrudescent  and  one 
indeterminate).  Five  of  six  patients  with  piperaquine 
concen  trations  lower  than  the  limit  of  quantiﬁ  cation 
were in the unsupervised group. Blood concentrations 
below the limit of quantiﬁ  cation were treated as zero and 
included in the analysis. The mean blood piperaquine 
concentration at day 7 was signiﬁ  cantly higher in the 293 
patients who were successfully treated than in six with 
recrudescence  or  reinfection  (74  [SD  39]  ng/mL v s  
34 [31] ng/mL, p=0·013).
Discussion
Both  artesunate-meﬂ  oquine  and  dihydroartemisinin-
piperaquine were highly eﬃ   cacious, eﬀ  ective, and well-
tolerated  treatments  for  uncomplicated  falciparum 
malaria  in  western  Myanmar.  Similar  high  cure  rates 
have  been  reported  previously  in  studies  in  Vietnam
7 
(56-day cure rate 98·7%), Cambodia
8 (28-day cure rate 
96·9%), and Thailand
9 (63-day cure rate 96·1%). Under 
normal conditions, without supervision of dosing after 
the  initial  consultation,  cure  rates  were  almost  100%. 
Since the eﬃ   cacy of incomplete regimens in these 3-day 
treatments is reduced, this rate suggests that nearly all 
patients completed their treatment as advised. In the case 
of artesunate-meﬂ  oquine, all the meﬂ  oquine and the ﬁ  rst 
dose of artesunate were given under supervision on the 
ﬁ  rst day, and in a previous study, this regimen (ie, 1-day 
treatment) was associated with a high (96·4%) cure rate.
5 
But for dihydroartemisinin-piperaquine, a third of the 
dose (ﬁ  rst-day treatment only) is certainly not enough to 
account  for  such  high  cure  rates,  so  adherence  was 
probably good. This assumption is lent support by the 
whole-blood piperaquine results, which indicated little 
diﬀ  erence between the supervised and non-supervised 
groups. 
The  artesunate-meﬂ  oquine  combination,  which  has 
been  the  national  protocol  for  falciparum  malaria  in 
Myanmar since 2002, has been used continuously since 
1996 in this area. The treatment has retained a high cure 
rate, and the fact that there has been no selection of 
resistance evident in this region of western Myanmar 
over  the  past  7  years  is  encouraging.  In  Thailand, 
resistance  to  meﬂ  oquine  monotherapy  arose  within 
7 years, but resistance to meﬂ  oquine after deployment of 
the combination threatment has fallen.
16 These results, 
indicating good adherence to prescribed regimens and 
sustained  high  eﬃ   cacy,  augur  well  for  more  general 
deployment  of  these  artemisinin-based  combinations.   
Meﬂ  oquine is associated with predictable gastrointestinal 
and CNS adverse eﬀ  ects. In previous studies, tolerability 
and drug absorption were both increased by splitting the 
25  mg/kg  dose.  In  this  study,  the  3-day  artesunate-
meﬂ  oquine  combination  treatment  was  started  with 
25  mg/kg  meﬂ  oquine  on  day  0,  by  contrast  with  a 
previous  study  we  did  in  the  same  region  in  which 
meﬂ  oquine was divided over day 1 (15 mg/kg) and day 2 
(10 mg/kg). This approach aimed to reduce the eﬀ  ects of 
poor  adherence,  which  was  thought  to  be  more  of  a 
concern than reduced oral bioavailability. Indeed, cure 
rates  were  better  in  this  study  (no  recrudescences  in 
159 patients) than in our earlier trial when meﬂ  oquine 
was taken over days 1 and 2 (seven recrudescences of 
180;  4%;  p=0·016).  This  ﬁ  nding  corroborates  our 
previous  suggestion
5  that,  if  the  treatment  cannot  be 
supervised, and the tablets are separate, the whole dose 
of meﬂ  oquine should be given on day 0 to ensure that it 
is  taken,  even  though  the  drug’s  absorption  and 
bioavailability might be less when taken as a single dose 
on day 0.
17
Vomiting  of  antimalarial  drugs  is  an  important 
consideration  in  treatment.  Early  vomiting  occurred  in 
only 2% of patients treated on the ﬁ  rst day with 25 mg/kg 
meﬂ  oquine.  This  proportion  is  lower  than  reported 
previously.
18  Dihydroartemisinin-piperaquine  treatment 
was  associated  with  a  similarly  low  frequency  of  early 
vomiting (2%) but had signiﬁ  cantly fewer other side-eﬀ  ects 
(dizziness  and  nausea),  particularly  in  the  ﬁ  rst  2  days. 
Vomiting on the next 2 days of treatment in supervised 
patients was infrequent and was not a major drawback in 
this study. The patients who took their medicines at home 
did not report any vomiting within 1 h after drug intake at 
all  whereas  in  the  supervised  group  some  patients  had 
early vomiting, although this reaction was mainly after the 
ﬁ  rst dose when febrile and ill. Thus, we think that some 
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Figure 3: Day 7 capillary whole-blood piperaquine concentrations in patients 
who took the day 2 and day 3 doses unsupervised at home, compared with 
those whose dose administration was supervised 
Bars show median and IQR. Articles
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patients in the non-supervised group might have vomited 
on days 1 and 2, but that this reaction was not reported. If 
so, and since they did not request extra medicines, they 
would have had an inadequate dose and cure rates might 
have  been  expected  to  fall.  Alternatively,  when  partly 
recovered and in the familiar setting of home, vomiting 
might be less likely. Patients should be informed clearly 
that in case of vomiting, extra tablets should be obtained. 
This  factor  is  particularly  important  with  dihydro-
artemisinin-piperaquine, since a third of the dose (ﬁ  rst 
day treatment only) is unlikely to be enough to cure the 
infection. 
During  follow-up,  patients  who  received  dihydro-
artemisinin-piperaquine  had  fewer  vivax  infections, 
though not signiﬁ  cantly (p=0·07), but had signiﬁ  cantly 
more  gametocyte  carriage  and  more  new  gametocyte 
appearances. 
Although the proportion of gametocytaemia at baseline, 
by  chance,  was  higher  in  the  dihydroartemisinin-
piperaquine  group,  the  rate  of  new  appearance  of 
gametocytaemia  was  also  signiﬁ  cantly  higher  in  this 
group than in the artesunate-meﬂ  oquine recipients. If the 
higher gametocyte carriage rate after dihydro  artemisinin-
piperaquine is conﬁ  rmed, it would represent a public-
health disadvantage because it would indicate increased 
transmissibility.  The  higher  gametocyte  carriage  rate 
might result from the lower dose of artemisinin derivative 
used in the dihydroartemisinin-piperaquine combination. 
This eﬀ  ect should be balanced against the advantages of 
simplicity of dosing, very high eﬃ   cacy and eﬀ  ectiveness, 
and  an  excellent  adverse-eﬀ  ect  proﬁ  le.  Vivax  malaria 
commonly followed falciparum malaria; indeed P vivax 
was by far the most common cause of malaria during the 
6-week  follow-up.  Mixed  infections  are  much  more 
frequent than recognised from admission blood smears.
19  
The  appearance  of  P  vivax  infection  after  an  eﬀ  ective 
treatment  presumably  represents  a  relapse.  These 
infections were particularly frequent (40%) in children 
under 5 years of age.
20 Both health providers and parents 
in this area need to be informed that there is a high risk of 
another malaria episode in young children, and parents 
should be encouraged to bring the children to the clinic if 
fever reappears.
Although  the  question  of  adherence  to  antimalarial 
drugs  is  much  debated,  there  are  no  deﬁ  nitions  or 
guidelines  to  interpret  incomplete  adherence  and  few 
studies  that  have  tried  to  measure  it.  A  recent  review 
identiﬁ  ed  only  16  trials  with  widely  diﬀ  ering  method-
ologies.
21 The use of blood concentration measurements 
to  assess  adherence  is  facilitated  by  the  availability  of 
simple but sensitive validated ﬁ  lter-paper assay methods 
such  as  that  for  piperaquine.  This  method  indicated 
generally  excellent  adherence  to  dihydroartemisinin-
piperaquine in our study, although the day 7 whole-blood 
piperaquine concentrations for the patients with treatment 
failure  were  lower  than  those  for  successfully  treated 
patients, suggesting that the terminal elimination phase 
of piperaquine is an important determinant of eﬃ   cacy.
22 
The  fact  that  treatment  success  was  high  in  this  large 
study even when two-thirds of the treatment doses were 
not supervised is important because—in practice—most 
antimalarial treatments are taken at home. However, since 
the drugs were given free (whereas people generally have 
to pay), operational eﬀ  ectiveness might diﬀ  er from that 
presented here. Education of patients and price subsidy 
are both likely to be important in ensuring good adherence 
to the prescribed regimens under normal conditions of 
use.
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In our setting, if the ﬁ  rst dose is supervised and a clear 
instruction  is  provided  to  the  patient  or  carer,  the 
eﬀ  ectiveness of the treatment equals its observed eﬃ   cacy. 
This  study  shows  that  both  combination  treatment 
regimens  are  eﬀ  ective,  even  when  self-administered. 
Dihydroartemisinin-piperaquine is a good alternative for 
artesunate-meﬂ  oquine  because  it  is  less  expensive, 
coformulated,  and  has  fewer  side-eﬀ  ects.  Dihydro-
artemisinin-piperaquine  has  the  poten  tial  to  play  an 
important part in future malaria manage  ment.
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